Perera Bhathika, Steward Charles, Courtenay Ken, Andrews Timothy, Shankar Rohit
Barnet, Enfield and Haringey Mental Health NHS Trust, London, UK.
Congenica Ltd, Cambridge, UK.
BJPsych Open. 2022 Aug 17;8(5):e157. doi: 10.1192/bjo.2022.554.
There is growing evidence for the use of pharmacogenomics in psychotropic prescribing. People with intellectual disabilities are disproportionately prescribed psychotropics and are at risk of polypharmacy. There is an urgent need for safeguards to prevent psychotropic overprescribing but it is equally crucial that this population is not left behind in such exciting initiatives. Understanding how genetic variations affect medications is a step towards personalised medicine. This may improve personalised prescribing for people with intellectual disabilities, especially given the high rate of psychiatric and behavioural problems in this population. Our editorial explores opportunities and challenges that pharmacogenomics offers for the challenges of polypharmacy and overprescribing of psychotropics in people with intellectual disabilities.
越来越多的证据表明药物基因组学可用于精神药物处方。智障人士被过度开具精神药物的比例过高，且有多重用药的风险。迫切需要采取保障措施以防止精神药物过度处方，但同样重要的是，在这些令人振奋的举措中不能将这一人群落下。了解基因变异如何影响药物是迈向个性化医疗的一步。这可能会改善为智障人士的个性化处方，特别是考虑到这一人群中精神和行为问题的高发率。我们的社论探讨了药物基因组学为智障人士多重用药和精神药物过度处方问题带来的机遇与挑战。
